InterCure Ltd. INCR has shown resilience in its H1 2024 performance despite facing significant challenges, according to equity research by Pablo Zuanic of Zuanic & Associates.
InterCure is a leading pharmaceutical/medical cannabis company based in Israel and a global leader outside North America. Despite the damage the Hamas attack and the state of war in Israel caused, the company managed to sustain operations and present a positive 2023 ER. The company is entitled to full compensation from the Israeli government for the damage taken.
28 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
18 Aug 2025 (In 3 weeks) Date | | 0.03 Cons. EPS | - EPS |
13 Dec 2024 Date | | - Cons. EPS | - EPS |
23 May 2024 Date | | - Cons. EPS | - EPS |
1 Apr 2024 Date | | - Cons. EPS | - EPS |
28 Aug 2025 (In 1 month) Date | | - Cons. EPS | - EPS |
18 Aug 2025 (In 3 weeks) Date | | 0.03 Cons. EPS | - EPS |
13 Dec 2024 Date | | - Cons. EPS | - EPS |
23 May 2024 Date | | - Cons. EPS | - EPS |
1 Apr 2024 Date | | - Cons. EPS | - EPS |
Drug Manufacturers - Specialty & Generic Industry | Healthcare Sector | Alexander Rabinovich CEO | NASDAQ (NMS) Exchange | M549GJ111 Cusip |
IL Country | 320 Employees | - Last Dividend | - Last Split | - IPO Date |
InterCure Ltd. is a prominent player in the medical cannabis industry, extending its footprint beyond its home country Israel to serve international markets. Founded in 1994 and based in Herzliya, Israel, the company has carved a niche in researching, cultivating, producing, and distributing pharmaceutical-grade cannabis and cannabis-based products tailored for medical applications. Besides its core operations in the cannabis sector, InterCure Ltd. also places strategic investments in the biomed sector, reflecting its broader vision in healthcare and medical innovations.